Evidence map›Paper›PMID 37163263›Full record

ArticleJAMA network open2023

Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department-Initiated Buprenorphine Programs.

Kimberly L Sue, Marek Chawarski, Leslie Curry, Ryan McNeil, Edouard Coupet, Robert P Schwartz, Christine Wilder, Judith I Tsui, Kathryn F Hawk, Gail D'Onofrio and 3 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kimberly L SueDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Marek ChawarskiDepartment of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut.
Leslie CurryHealth Policy and Management, Yale School of Public Health, New Haven, Connecticut.
Ryan McNeilDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Edouard CoupetYale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut.
Robert P SchwartzFriends Research Institute, Baltimore, Maryland.
Christine WilderDepartment of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Judith I TsuiDepartment of Medicine, University of Washington School of Medicine, Seattle.
Kathryn F HawkYale Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut.
Gail D'OnofrioDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Patrick G O'ConnorDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
David A FiellinDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
E Jennifer EdelmanDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Yale University · USFriends Research Institute · USUniversity of Cincinnati Medical Center · USUniversity of Washington · US

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
Clinical Trials Network: Mid-Atlantic Integrated Care Research CollaborativeUG1DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 2015 to 2019
$11.0M
NCATS NIH HHS UL1 TR001863NIDA NIH HHS HHSN271201400028CNIDA NIH HHS HHSN271201500065CNIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015831
6 · The paper itself

Abstract

Importance: An increasing number of emergency departments (EDs) are initiating buprenorphine for opioid use disorder (OUD) and linking patients to ongoing community-based treatment, yet community-based clinician and staff perspectives regarding this practice have not been characterized. Objective: To explore perspectives and experiences regarding ED-initiated buprenorphine among community-based clinicians and staff in geographically distinct regions. Design, Setting, and Participants: This qualitative study reports findings from Project ED Health, a hybrid type 3 effectiveness-implementation study designed to evaluate the impact of implementation facilitation on ED-initiated buprenorphine with referral to ongoing medication treatment. Clinicians and staff from community-based treatment programs were identified by urban academic EDs as potential referral sites for ongoing OUD treatment in 4 cities across the US in a formative evaluation as having the capability to continue medication treatment. Focus groups were held from April 1, 2018, to January 11, 2019, to examine community OUD treatment clinician and staff perspectives on accepting patients who have received ED-initiated buprenorphine. Data were analyzed from August 2020 to August 2022. Main Outcomes and Measures: Data collection and analysis were grounded in the Promoting Action on Research Implementation in Health Services (PARIHS) implementation science framework, focusing on domains including evidence, context, and facilitation. Results: A total of 103 individuals (mean [SD] age, 45.3 [12.0] years; 76 female and 64 White) participated in 14 focus groups (groups ranged from 3-22 participants). Participants shared negative attitudes toward buprenorphine and variable attitudes toward ED-initiated buprenorphine. Prominent barriers included the community site treatment capacity and structure as well as payment and regulatory barriers. Perceived factors that could facilitate this model included additional substance use disorder training for ED staff, referrals and communication, greater inclusion of peer navigators, and addressing sociostructural marginalization that patients faced. Conclusions and Relevance: In this study of community-based clinicians and staff positioned to deliver OUD treatment, participants reported many barriers to successful linkages for patients who received ED-initiated buprenorphine. Strategies to improve these linkages included educating communities and programs, modeling low-barrier philosophies, and using additional staff trained in addiction as resources to improve transitions from EDs to community partners.

Indexed as

BuprenorphineOpioid-Related DisordersEmergency Service, HospitalFemaleHealth ServicesHumansMiddle AgedOpiate Substitution TreatmentBuprenorphine

Identifiers

PMID37163263
PMCPMC10173026
OpenAlexW4376121911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.